Problems With 340B? GAO Is Now Gathering Information From Drug Manufacturers
This article was originally published in The Pink Sheet Daily
Executive Summary
The Government Accountability Office has begun interviewing pharmaceutical manufacturers about their experiences with the 340B drug discount program in preparation for a report mandated by the Affordable Care Act.
You may also be interested in...
GAO And Legislators Pushing HHS For Stronger 340B Oversight
The Government Accountability Office is proposing several recommendations to strengthen oversight of the 340B drug discount program, but says the HHS Health Resources and Services Administration wants to take other measures that GAO believes are insufficient.
GAO And Legislators Pushing HHS For Stronger 340B Oversight
The Government Accountability Office is proposing several recommendations to strengthen oversight of the 340B drug discount program, but says the HHS Health Resources and Services Administration wants to take other measures that GAO believes are insufficient.
Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities
U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.